Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial.

Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial.

<h4>Background</h4>Genital herpes simplex infection affects more than 500 million people worldwide. We have previously shown that COR-1, a therapeutic HSV-2 polynucleotide vaccine candidate, is safe and well tolerated in healthy subjects.<h4>Objective</h4>Here, we present a s...

Full description

Bibliographic Details
Main Authors: Janin Chandra, Wai-Ping Woo, Julie L Dutton, Yan Xu, Bo Li, Sally Kinrade, Julian Druce, Neil Finlayson, Paul Griffin, Kerry J Laing, David M Koelle, Ian H Frazer
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0226320

Internet

https://doi.org/10.1371/journal.pone.0226320

Similar Items